Open Access Research article

TWEAK and Fn14 expression in the pathogenesis of joint inflammation and bone erosion in rheumatoid arthritis

Anak ASSK Dharmapatni1*, Malcolm D Smith2, Tania N Crotti1, Christopher A Holding1, Cristina Vincent4, Helen M Weedon2, Andrew CW Zannettino36, Timothy S Zheng4, David M Findlay56, Gerald J Atkins56 and David R Haynes1

Author Affiliations

1 Discipline of Anatomy and Pathology, School of Medical Sciences, University of Adelaide, Frome Road, Adelaide, SA 5005, Australia

2 Rheumatology Research Unit, Repatriation General Hospital, Daws Road, Adelaide, SA 5041, Australia

3 Myeloma Research Laboratory, Bone and Cancer Laboratories, Division of Haematology, Institute of Medical & Veterinary Science, Frome Road, Adelaide, SA 5005, Australia

4 Immunology, Biogen Idec Inc., Cambridge Centre, Cambridge, MA 02142, USA

5 Bone Cell Biology Group, Discipline of Orthopaedics and Trauma, University of Adelaide, Frome Road, Adelaide, SA 5005, Australia

6 Hanson Institute, Frome Road, Adelaide, SA 5005, Australia

For all author emails, please log on.

Arthritis Research & Therapy 2011, 13:R51  doi:10.1186/ar3294

Published: 24 March 2011

Abstract

Introduction

TNF-like weak inducer of apoptosis (TWEAK) has been proposed as a mediator of inflammation and bone erosion in rheumatoid arthritis (RA). This study aimed to investigate TWEAK and TWEAK receptor (Fn14) expression in synovial tissue from patients with active and inactive rheumatoid arthritis (RA), osteoarthritis (OA) and normal controls and assess soluble (s)TWEAK levels in the synovial fluids from patients with active RA and OA. Effects of sTWEAK on osteoclasts and osteoblasts were investigated in vitro.

Methods

TWEAK and Fn14 expression were detected in synovial tissues by immunohistochemistry (IHC). Selected tissues were dual labelled with antibodies specific for TWEAK and lineage-selective cell surface markers CD68, Tryptase G, CD22 and CD38. TWEAK mRNA expression was examined in human peripheral blood mononuclear cells (PBMC) sorted on the basis of their expression of CD22. sTWEAK was detected in synovial fluid from OA and RA patients by ELISA. The effect of sTWEAK on PBMC and RAW 264.7 osteoclastogenesis was examined. The effect of sTWEAK on cell surface receptor activator of NF Kappa B Ligand (RANKL) expression by human osteoblasts was determined by flow cytometry.

Results

TWEAK and Fn14 expression were significantly higher in synovial tissue from all patient groups compared to the synovial tissue from control subjects (P < 0.05). TWEAK was significantly higher in active compared with inactive RA tissues (P < 0.05). TWEAK expression co-localised with a subset of CD38+ plasma cells and with CD22+ B-lymphocytes in RA tissues. Abundant TWEAK mRNA expression was detected in normal human CD22+ B cells. Higher levels of sTWEAK were observed in synovial fluids isolated from active RA compared with OA patients. sTWEAK did not stimulate osteoclast formation directly from PBMC, however, sTWEAK induced the surface expression of RANKL by human immature, STRO-1+ osteoblasts.

Conclusions

The expression of TWEAK by CD22+ B cells and CD38+ plasma cells in RA synovium represents a novel potential pathogenic pathway. High levels of sTWEAK in active RA synovial fluid and of TWEAK and Fn14 in active RA tissue, together with the effect of TWEAK to induce osteoblastic RANKL expression, is consistent with TWEAK/Fn14 signalling being important in the pathogenesis of inflammation and bone erosion in RA.